Fatal cholestatic jaundice in elderly patients taking benoxaprofen.
نویسندگان
چکیده
منابع مشابه
Fatal cholestatic jaundice in elderly patients taking benoxaprofen.
All patients were women over the age of 80 years and were treated with benoxaprofen 600 mg daily. Case 1-An 86-year-old woman presented in January 1981 with a confusional state. She had a smooth firm liver palpable 6 cm below the costal margin, erythrocyte sedimentation rate of 75 mm in first hour, and a slightly raised alkaline phosphatase activity. She recovered spontaneously and was not seen...
متن کاملFamilial Intrahepatic Cholestatic Jaundice
Recurrent jaundice due to intrahepatic cholestasis is reported most often in adults. Some varieties are familial and are associated with failure of excretion of conjugated bilirubin by the liver cell. The original descriptions of these types given by Rotor, Manahan, and Florentin (1948) and Dubin and Johnson (1954) concerned patients with a benign recurrent jaundice. The diseases described by t...
متن کاملCephalexin Induced Cholestatic Jaundice
Cephalexin is a very commonly prescribed orally administered antibiotic which has many potential side effects. Amongst these cholestatic jaundice has been infrequently reported as an adverse reaction. We present a case of a 57-year-old male who exhibited features of cholestatic jaundice including elevated liver function tests (LFTs) after taking cephalexin and showed improvement on removal of t...
متن کاملTrifluoperazine-Induced Cholestatic Jaundice
Liver injury occurs with many drugs; therefore, a thorough work up is important for establishing the diagnosis. We report a case of trifluoperazine-induced cholestatic jaundice. A 44-year old male with schizoaffective disorder developed an increase in liver enzymes and jaundice after starting treatment with trifluoperazine. Workup for other potential etiologies was negative.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: BMJ
سال: 1982
ISSN: 0959-8138,1468-5833
DOI: 10.1136/bmj.284.6326.1372